Insights - Agenus (AGEN) reported on Tuesday updated results from an open-label, single-arm phase 2 study of Prophage, the company’s cancer vaccine, in glioblastoma multiforme. Patients treated with Prophage plus standard of care … Continue Reading
Read nowResearch - AcelRx (ACRX) will receive an approval decision form the US FDA next month for Zalviso. Read more, and understand our point of view, here.
PremiumResearch - Two technical trade ideas, both names PropThink has followed for some time, with quality, fundamental backstories.
PremiumInsights - StemCells, Inc. (STEM) announced on Thursday interim results from a phase 1/2 trial of its HuCNS-SC cells in dry age-related macular degeneration (AMD). The results are encouraging in a field that has … Continue Reading
Read nowInsights - It’s June 18, five days past a self-imposed deadline, and Aspen Investment Fund is nowhere to be seen with its alleged $640 million bid to buy Vivus, Inc. … Continue Reading
Read nowResearch - Orexigen Therapeutics (OREX) broke above $7 in the Tuesday trading session, a day before the FDA issues a decision on the New Drug Application for NB32 (Contrave) as … Continue Reading
PremiumInsights - In an SEC filing on Wednesday, Retrophin (RTRX) CEO Martin Shkreli reported the sale of 292,400 shares of RTRX common stock worth $4.4 million dollars last Friday, nearly 10% … Continue Reading
Read now
